MYC and diffuse large B-cell lymphoma: Despite the generally favourable outcome, relapses still occur in 10 to 20% of patients with limited stage DLBCL and 5‐year OS ranges between 75% and 94%, which suggests that salvage of relapses is frequently unsuccessful.6, 7, 8, 9, 10 Clinical prognostic models only partially identify patients at risk for relapse.2, 11 Biological tumour characteristics such as cell of origin and especially presence of MYC translocation have prognostic significance in DLBCL.12, 13